Paris expertise center for organ transplantationThe Paris Transplant Group (PTG) is developing a personalized approach for transplant medicine that integrates multidimensional information derived from standard of care (clinical and biological data, histology and immunology) together with novel information coming from cutting edge technologies in immunology, molecular biology, genetics and biomarkers.
|
Research at PTG
|
A multi-organ approachThe team includes several departments in kidney, heart, lung and liver transplantation, which are known as reference centres. Our consortium includes leading national kidney transplant centres totalling more than 530 transplants on average each year. The centres dedicated to heart transplant represent more than 80% of the overall national heart transplant activity (150 transplants on average each year) and the centre dedicated to lung transplant is the leader in Paris area (75 transplants on average each year). This is one of the largest multi-organ transplantation cohort worldwide.
more than
organ transplants per year
|
Integrative researchOver time, we have developed a particular scientific approach closely combining clinical investigations and statistics. The probabilistic mathematical tool is used in an integrative thinking approach, coupled at many levels with questions, insights and clinical investigations. We called this approach "integrative epidemiology". This approach received the “Grand Prix de l’Académie des Sciences 2013” and the "Grand Prix de l'Académie de Médecine 2018" by the French Academy of Medicine in Paris (France). The rapid advances in medicine and sciences led to increased specialisation. The integrative epidemiology sets up an opposite approach where medical specialties and fundamental sciences are centralised around epidemiology.
|
|
|
Data-driven scienceSo far, many results derived from large registries (UNOS in the US, Eurotransplant, National French Agency for Organ Procurement). They have a high value for descriptive purposes (prevalence and incidence), they do not provide per se insights in pathogenesis, risk prediction and personalised transplant medicine. Our approach uses exceptionally large prospective unselected cohorts with a very high level of detail (deep phenotyping), to test cutting-edge technologies with powerful and robust methodological tools.
The large quantity of information gathered from thousands of patients at multiple points in time allows us to take advantage of big data / smart data approach. |
iBox: Prediction system for RENAL allograft loss
|
This is the first international study of risk prediction in kidney transplant recipients, developed and validated across several large independent populations and in randomised controlled clinical trials. The iBox score represents a novel integration of demographic, functional, histological, and immunological factors that can be implemented in routine clinical practice. It has potential to upgrade the shared decision making process for transplant patients and represents a valid and early surrogate endpoint for clinical trials and drug development in transplantation.
Read more about iBox |
|